Halma plc

LSE HLMA.L

Halma plc Free Cash Flow Yield on January 14, 2025: 3.43%

Halma plc Free Cash Flow Yield is 3.43% on January 14, 2025, a 49.17% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Halma plc 52-week high Free Cash Flow Yield is 4.12% on April 19, 2024, which is 19.99% above the current Free Cash Flow Yield.
  • Halma plc 52-week low Free Cash Flow Yield is 2.12% on February 26, 2024, which is -38.27% below the current Free Cash Flow Yield.
  • Halma plc average Free Cash Flow Yield for the last 52 weeks is 3.20%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
LSE: HLMA.L

Halma plc

CEO Mr. Marc Arthur Ronchetti
IPO Date July 1, 1988
Location United Kingdom
Headquarters Misbourne Court
Employees 8,000
Sector Health Care
Industries
Description

Halma plc, through its subsidiaries, provides technology solutions in the safety, health, and environmental markets. It operates through three segments: Safety, Environmental & Analysis, and Medical. The Safety segment provides fire detection, specialist fire suppression, elevator safety, security sensors, people and vehicle flow technologies, specialized interlocks that control critical processes safely, and explosion protection and corrosion monitoring systems. This segment serves elevator safety, fire suppression, people and vehicle flow, fire detection, pressure management, industrial access control, and safe storage and transfer markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; water, air and gases monitoring technologies; instruments that detect hazardous gases and analyses air quality; and systems for water analysis and treatment. It serves the optical analysis, water analysis and treatment, gas detection, and environmental monitoring markets. The Medical segment provides critical fluidic components used by medical diagnostics and original equipment manufacturers; laboratory devices and systems that provide information to understand patient health and enable providers to make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable positive outcomes across clinical specialties. This segment serves the life sciences, health assessment, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.

Similar companies

CRDA.L

Croda International Plc

USD 38.05

-2.23%

ITRK.L

Intertek Group plc

USD 58.16

-0.66%

BNZL.L

Bunzl plc

USD 40.38

0.03%

SPX.L

Spirax-Sarco Engineering plc

USD 78.56

-0.22%

AHT.L

Ashtead Group plc

USD 61.33

3.34%

StockViz Staff

January 15, 2025

Any question? Send us an email